8 research outputs found
An Environmental Geochemical Study Of Connecticut Marsh Sediments
Core material from Spartina-dominated Housatonic and Connecticut River estuarine sites (ranging from low to high marsh) were investigated in order to test the hypothesis that organic and inorganic pollutants preferentially accumulate in the low marsh environment. Radiometric data indicate that the low marsh setting experienced sedimentation rates an order of magnitude greater than that of the mid to high marsh. The low marsh sediments from the Housatonic tend to have significantly higher concentrations of trace metals (e.g., Cu and Zn, likely contributed by brass mills formerly active upstream). Petrographic examination of the samples under reflected white and blue light reveals fly ash, coke, char and coal particles. Molecular organic analysis by pyrolysis-gas chromatography/mass spectrometry demonstrates that the sediments enriched in anthropogenic trace metals and carbonaceous particles are also enriched in polycyclic aromatic hydrocarbons (PAHs) such as pyrene, chrysene and benzopyrenes, most likely combustion-derived. Long chain alkylamides are also unusually abundant in the pyrolyzates of these impacted sediments. These compounds are likely derived from bacterial organic matter in the sediments and we suggest that their presence could signal organic (i.e., sewage) contamination. These observations are reinforced by multivariate analysis of the combined organic/inorganic data set. The sediment cores serve in effect as archives documenting industrial pollution and environmental change in the estuaries over the last two centuries. The low marsh environments studied apparently provide a significant sink for pollutants when compared to mid and high marsh environments
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
Introduction:
The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures.
Methods:
In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025.
Findings:
Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation.
Interpretation:
After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification
HIGH RESOURCE UTILIZATION FOR NON-CARDIAC HOSPITAL ADMISSIONS FOR ADULTS WITH CONGENITAL HEART DISEASE
Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: A randomised controlled trial
Objective: To evaluate an informed shared decisionmaking
programme (ISDM-P) for people with type 2
diabetes under high fidelity conditions.
Design: Randomised, single-blinded trial with sham
control intervention and follow-up of 6 months.
Setting: Single-centre diabetes clinic providing care
according to the national disease management
programme in Germany.
Participants: 154 people with type 2 diabetes without
diagnosis of ischaemic heart disease or stroke.
Interventions: The ISDM-P is executed by diabetes
educators. Core component is a patient decision aid on
the prevention of myocardial infarction supplemented
by a 90 min group teaching session. The structurally
equivalent control intervention addresses stress issues.
Main outcome measures: Primary outcome was risk
comprehension, including realistic expectations about
benefits and harms of interventions. It was assessed by
a 12-item questionnaire after the teaching session when
patients set and prioritise their treatment goals. Key
secondary outcome was adherence to treatment goals,
operationalised as achievement of individual goals and
medication uptake. ISDM-P teaching sessions were
video-taped to monitor intervention fidelity.
Results: 72 of 77 ISDM-P and 71 of 77 control
patients completed the questionnaire (score 0–12).
ISDM-P patients achieved higher levels of risk
comprehension, mean score 8.25 vs 2.62, difference
5.63 (95% CI 4.82 to 6.44), and realistic expectations
(score 0–6), 4.51 vs 0.85, 3.67 (3.23 to 4.11). More
ISDM-P patients wished to take statins, 59.2% vs
30.4%, 28.7% (12.9% to 44.5%); more prioritised
blood pressure control, 51.4% vs 25.7%, and fewer
intensive glucose control, 33.3% vs 60%, p=0.002.
More ISDM-P patients achieved their glycated
haemoglobin goals, 95.8% vs 85.7%, 10.1% (0.6% to
19.5%). Achievement of prioritised goals and
medication uptake were comparable between groups.
Conclusions: The ISDM-P on preventive measures in
type 2 diabetes was effective under high fidelity
conditions. Involvement of diabetes educators may
facilitate implementation of the informed shared
decision-making.
Trial registration number: ISRCTN84636255
Complementary and alternative medicine is positively associated with religiousness/spirituality
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance
Purpose: Post-treatment follow-up in women with cervical pre-cancers (CIN3) is mandatory due to relapse in up to 10% of patients. Standard follow-up based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our prospective, multicenter, observational study was to test the hypothesis that an individualized viral-cellular-junction test (vcj-PCR) combined with cytology has a lower false positive rate for the prediction of recurrence compared to standard co-testing. Methods: Pre-surgical cervical swabs served for the identification of HPV16/18 DNA integration sites by next-generation-sequencing (NGS). Samples taken at 6, 12 and 24 months post-surgery were evaluated by cytology, hrHPV-DNA and the patients’ individual HPV-integration sites (vcj-PCR on the basis of NGS). Results: Integration sites were detected in 48 of 445 patients (10.8%), 39 of them had valid follow-up data. The false positive rate was 18.2% (95% CI 8.6–34.4%) for standard hrHPV/cytology at six months compared to 12.1% (95% CI 4.8–27.3%) for vcj-PCR/cytology, respectively (McNemar p = 0.50). Six patients developed recurrences (1 CIN2, 5 CIN3) during follow-up. Standard co-testing detected all, whereas vcj-PCR/cytology detected only five patients with recurrences. Data of 269 patients without evidence of HPV16/18 integration were subject to post-hoc analyses. Standard co-testing revealed a false positive rate of 15.7% (95% CI 11.7–20.7%) and predicted ten of fourteen recurrences at six months. Conclusions: Although highly specific on its own vcj-PCR could not detect all recurrent CIN2/3. Possible reasons for this unexpected result may be multifocal lesions, intratumoral heterogeneity with respect to HPV integration and/or incident CIN
Gene expression signature predicts rate of type 1 diabetes progressionResearch in context
Summary: Background: Type 1 diabetes is a complex heterogenous autoimmune disease without therapeutic interventions available to prevent or reverse the disease. This study aimed to identify transcriptional changes associated with the disease progression in patients with recent-onset type 1 diabetes. Methods: Whole-blood samples were collected as part of the INNODIA study at baseline and 12 months after diagnosis of type 1 diabetes. We used linear mixed-effects modelling on RNA-seq data to identify genes associated with age, sex, or disease progression. Cell-type proportions were estimated from the RNA-seq data using computational deconvolution. Associations to clinical variables were estimated using Pearson's or point-biserial correlation for continuous and dichotomous variables, respectively, using only complete pairs of observations. Findings: We found that genes and pathways related to innate immunity were downregulated during the first year after diagnosis. Significant associations of the gene expression changes were found with ZnT8A autoantibody positivity. Rate of change in the expression of 16 genes between baseline and 12 months was found to predict the decline in C-peptide at 24 months. Interestingly and consistent with earlier reports, increased B cell levels and decreased neutrophil levels were associated with the rapid progression. Interpretation: There is considerable individual variation in the rate of progression from appearance of type 1 diabetes-specific autoantibodies to clinical disease. Patient stratification and prediction of disease progression can help in developing more personalised therapeutic strategies for different disease endotypes. Funding: A full list of funding bodies can be found under Acknowledgments